Zacks.com Announces That Nadine Wong Highlights the Following Stock: Chiron.

CHICAGO -- It's flu season again, but one of the largest vaccine makers will not have a leading product available to the public this year. Nadine Wong explains this company's setback, how it will impact its full year earnings, and what investors should do about it. Read about Chiron (NASDAQ:CHIR). Nadine Wong is editor of the BioTech Stock Report newsletter. Click here for the full story exclusively on Zacks.com: http://at.zacks.com/?id=84

Here are the highlights from the Featured Expert column:

Chiron (NASDAQ:CHIR), the world's second largest flu vaccine maker thought its problems with their flu vaccine, Fluvirin, were behind it. Then, on October 5, 2004 Chiron said it would not supply its Fluvirin vaccine for the 2004-2005 flu season as the company's license to manufacture Fluvirin was suspended for three months by the United Kingdom Medicines and Healthcare Products regulatory body.

As a result of the license suspension, Chiron does not expect to record any sales of Fluvirin for the 2004-05 season, and disaffirms its previous full-year 2004 pro-forma earnings guidance of $1.80-$1.90 that at one time the company thought earnings would come in the low end of this range. Chiron currently expects full-year 2004 pro-forma earnings of between $0.70-$0.80.

In its conference call, Chiron said it is committed to ensure an adequate vaccine supply for the 2005-2006 influenza season. Once Chiron has resolved its problems with its Liverpool manufacturing facility, Chiron's shares have the potential to climb back.

Read Nadine Wong's complete commentary by clicking: http://at.zacks.com/?id=85

About Zacks Featured Experts

To be a successful investor you need professional advice. Experts who know what they're talking about and can help you achieve your financial goals in good markets...and especially in bad ones will help you improve your portfolio. That is why Zacks Investment Research has assembled the best investment experts in the business to offer their powerful advisory newsletters to you on all the major investment topics: Stocks, Mutual Funds, Bonds, Options, Futures etc.

Recommendations from Featured Experts Highlighted in FREE Investment Newsletter

The best way to tap into the powerful advice from these experts is through our free weekly e-mail newsletter, "Profit from the Pros". Each week we highlight several Featured Experts in this free e-mail newsletter. Get your free subscription to "Profit from the Pros" at: http://at.zacks.com/?id=86

About Zacks

Zacks.com is a property of Zacks Investment Research, Inc., which was formed in 1978 to compile, analyze, and distribute investment research to both institutional and individual investors. The guiding principle behind our work is the belief that investment experts, such as brokerage analysts and investment newsletter writers, have superior knowledge about how to invest successfully. Our goal is to unlock their profitable insights for our customers. And there is no better way to enjoy this investment success, than with a FREE subscription to "Profit from the Pros" weekly e-mail newsletter. For your free newsletter, visit http://at.zacks.com/?id=87

Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.

Disclaimer: Past performance does not guarantee future results. Investors should always research companies and securities before making any investments. Nothing herein should be construed as an offer or solicitation to buy or sell any security.